North China Pharmaceutical (SHA:600812) withdrew the product registration of its polymyxin B sulfate injection, according to a Tuesday filing with the Shanghai Stock Exchange.
The drug was used for urinary tract, meningeal, and blood infections caused by the Pseudomonas aeruginosa bacteria, the filing said.